Comprehensive Stock Comparison
Compare Sonida Senior Living, Inc. (SNDA) vs Fresenius Medical Care AG & Co. KGaA (FMS) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | SNDA | 19.2% revenue growth vs FMS's 1.5% |
| Quality / Margins | FMS | 5.0% net margin vs SNDA's -12.4% |
| Stability / Safety | FMS | Beta 0.40 vs SNDA's 1.06, lower leverage |
| Dividends | SNDA | 0.6% yield; FMS pays no meaningful dividend |
| Momentum (1Y) | SNDA | +47.7% vs FMS's +0.2% |
| Efficiency (ROA) | FMS | 3.2% ROA vs SNDA's -5.4%, ROIC 5.6% vs -1.7% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Sonida Senior Living operates senior housing communities across the United States, providing independent living, assisted living, and memory care services. The company generates revenue primarily from resident fees — including monthly rent and service charges — with its assisted living and memory care segments typically commanding higher rates due to the specialized care provided. Its competitive advantage lies in its operational expertise in managing a portfolio of owned communities, which creates economies of scale and allows for consistent service delivery across locations.
Fresenius Medical Care is a global leader in dialysis care and products for patients with chronic kidney failure. It generates revenue through two main segments: dialysis services (about 75% of revenue) from its network of outpatient clinics and hospital contracts, and dialysis products (about 25%) including machines, dialyzers, and related supplies. The company's key advantage is its vertically integrated model—combining clinics, products, and services—which creates patient stickiness and economies of scale in the capital-intensive dialysis industry.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
FMS leads in 4 of 6 categories (Financial Metrics, Valuation Metrics). SNDA leads in 1 (Total Returns). 1 tied.
Financial Metrics (TTM)
FMS is the larger business by revenue, generating $19.6B annually — 52.3x SNDA's $375M. FMS is the more profitable business, keeping 5.0% of every revenue dollar as net income compared to SNDA's -12.4%. On growth, SNDA holds the edge at +31.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | SNDASonida Senior Liv… | FMSFresenius Medical… |
|---|---|---|
| RevenueTrailing 12 months | $375M | $19.6B |
| EBITDAEarnings before interest/tax | $40M | $3.3B |
| Net IncomeAfter-tax profit | -$47M | $978M |
| Free Cash FlowCash after capex | -$10M | $1.2B |
| Gross MarginGross profit ÷ Revenue | +91.4% | +25.6% |
| Operating MarginEBIT ÷ Revenue | -4.0% | +9.3% |
| Net MarginNet income ÷ Revenue | -12.4% | +5.0% |
| FCF MarginFCF ÷ Revenue | -2.7% | +6.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | +31.2% | -0.3% |
| EPS Growth (YoY)Latest quarter vs prior year | -59.2% | +8.5% |
Valuation Metrics
On an enterprise value basis, FMS's 6.3x EV/EBITDA is more attractive than SNDA's 45.0x.
| Metric | SNDASonida Senior Liv… | FMSFresenius Medical… |
|---|---|---|
| Market CapShares × price | $682M | $13.6B |
| Enterprise ValueMkt cap + debt − cash | $1.3B | $24.4B |
| Trailing P/EPrice ÷ TTM EPS | -66.46x | 11.84x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 9.89x |
| PEG RatioP/E ÷ EPS growth rate | — | 2.32x |
| EV / EBITDAEnterprise value multiple | 45.04x | 6.33x |
| Price / SalesMarket cap ÷ Revenue | 2.24x | 0.59x |
| Price / BookPrice ÷ Book value/share | 3.91x | 0.81x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
FMS delivers a 6.8% return on equity — every $100 of shareholder capital generates $7 in annual profit, vs $-54 for SNDA. FMS carries lower financial leverage with a 0.76x debt-to-equity ratio, signaling a more conservative balance sheet compared to SNDA's 5.03x. On the Piotroski fundamental quality scale (0–9), FMS scores 5/9 vs SNDA's 4/9, reflecting solid financial health.
| Metric | SNDASonida Senior Liv… | FMSFresenius Medical… |
|---|---|---|
| ROE (TTM)Return on equity | -53.8% | +6.8% |
| ROA (TTM)Return on assets | -5.4% | +3.2% |
| ROICReturn on invested capital | -1.7% | +5.6% |
| ROCEReturn on capital employed | -2.3% | +6.9% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 5 |
| Debt / EquityFinancial leverage | 5.03x | 0.76x |
| Net DebtTotal debt minus cash | $634M | $9.2B |
| Cash & Equiv.Liquid assets | $17M | $1.6B |
| Total DebtShort + long-term debt | $651M | $10.8B |
| Interest CoverageEBIT ÷ Interest expense | -0.26x | 6.84x |
Total Returns (with DRIP)
A $10,000 investment in SNDA five years ago would be worth $12,300 today (with dividends reinvested), compared to $7,718 for FMS. Over the past 12 months, SNDA leads with a +47.7% total return vs FMS's +0.2%. The 3-year compound annual growth rate (CAGR) favors SNDA at 45.5% vs FMS's 9.1% — a key indicator of consistent wealth creation.
| Metric | SNDASonida Senior Liv… | FMSFresenius Medical… |
|---|---|---|
| YTD ReturnYear-to-date | +12.4% | -0.2% |
| 1-Year ReturnPast 12 months | +47.7% | +0.2% |
| 3-Year ReturnCumulative with dividends | +208.3% | +29.7% |
| 5-Year ReturnCumulative with dividends | +23.0% | -22.8% |
| 10-Year ReturnCumulative with dividends | -86.0% | -28.5% |
| CAGR (3Y)Annualised 3-year return | +45.5% | +9.1% |
Risk & Volatility
FMS is the less volatile stock with a 0.40 beta — it tends to amplify market swings less than SNDA's 1.06 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. SNDA currently trades 98.6% from its 52-week high vs FMS's 77.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | SNDASonida Senior Liv… | FMSFresenius Medical… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.06x | 0.40x |
| 52-Week HighHighest price in past year | $36.40 | $30.46 |
| 52-Week LowLowest price in past year | $19.34 | $20.95 |
| % of 52W HighCurrent price vs 52-week peak | +98.6% | +77.0% |
| RSI (14)Momentum oscillator 0–100 | 70.7 | 49.0 |
| Avg Volume (50D)Average daily shares traded | 39K | 518K |
Analyst Outlook
Wall Street rates SNDA as "Hold" and FMS as "Hold". Consensus price targets imply 19.4% upside for FMS (target: $28) vs -12.2% for SNDA (target: $32). SNDA is the only dividend payer here at 0.56% yield — a key consideration for income-focused portfolios.
| Metric | SNDASonida Senior Liv… | FMSFresenius Medical… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Hold |
| Price TargetConsensus 12-month target | $31.50 | $28.00 |
| # AnalystsCovering analysts | 2 | 18 |
| Dividend YieldAnnual dividend ÷ price | +0.6% | — |
| Dividend StreakConsecutive years of raises | 0 | 3 |
| Dividend / ShareAnnual DPS | $0.20 | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Mar 20 | Feb 26 | Change |
|---|---|---|---|
| Sonida Senior Livin… (SNDA) | 100 | 92.74 | -7.3% |
| Fresenius Medical C… (FMS) | 100 | 58.23 | -41.8% |
Sonida Senior Livin… (SNDA) returned +23% over 5 years vs Fresenius Medical C… (FMS)'s -23%. A $10,000 investment in SNDA 5 years ago would be worth $12,300 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Sonida Senior Livin… (SNDA) | $447M | $304M | -32.0% |
| Fresenius Medical C… (FMS) | $17.0B | $19.6B | +15.3% |
Fresenius Medical Care AG & Co. KGaA's revenue grew from $17.0B (2016) to $19.6B (2025) — a 1.6% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Sonida Senior Livin… (SNDA) | -6.3% | -0.7% | +89.2% |
| Fresenius Medical C… (FMS) | 6.9% | 5.0% | -28.2% |
Fresenius Medical Care AG & Co. KGaA's net margin went from 7% (2016) to 5% (2025).
Chart 4P/E Ratio History — 9 Years
| Stock | 2017 | 2025 | Change |
|---|---|---|---|
| Fresenius Medical C… (FMS) | 25.3 | 14.2 | -43.9% |
Fresenius Medical Care AG & Co. KGaA has traded in a 10x–39x P/E range over 9 years; current trailing P/E is ~12x.
Chart 5EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Sonida Senior Livin… (SNDA) | -14.54 | -0.54 | +96.3% |
| Fresenius Medical C… (FMS) | 1.87 | 1.68 | -10.2% |
Fresenius Medical Care AG & Co. KGaA's EPS grew from $1.87 (2016) to $1.68 (2025) — a -1% CAGR.
Chart 6Free Cash Flow — 5 Years
Sonida Senior Living, Inc. generated $-27M FCF in 2024 (+31% vs 2021). Fresenius Medical Care AG & Co. KGaA generated $0M FCF in 2025 (-100% vs 2021).
SNDA vs FMS: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is SNDA or FMS a better buy right now?
Fresenius Medical Care AG & Co. KGaA (FMS) offers the better valuation at 11.8x trailing P/E (9.9x forward), making it the more compelling value choice. Analysts rate Sonida Senior Living, Inc. (SNDA) a "Hold" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — SNDA or FMS?
Over the past 5 years, Sonida Senior Living, Inc. (SNDA) delivered a total return of +23.0%, compared to -22.8% for Fresenius Medical Care AG & Co. KGaA (FMS). A $10,000 investment in SNDA five years ago would be worth approximately $12K today (assuming dividends reinvested). Over 10 years, the gap is even starker: FMS returned -28.5% versus SNDA's -86.0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — SNDA or FMS?
By beta (market sensitivity over 5 years), Fresenius Medical Care AG & Co. KGaA (FMS) is the lower-risk stock at 0.40β versus Sonida Senior Living, Inc.'s 1.06β — meaning SNDA is approximately 165% more volatile than FMS relative to the S&P 500. On balance sheet safety, Fresenius Medical Care AG & Co. KGaA (FMS) carries a lower debt/equity ratio of 76% versus 5% for Sonida Senior Living, Inc. — giving it more financial flexibility in a downturn.
04Which has better profit margins — SNDA or FMS?
Fresenius Medical Care AG & Co. KGaA (FMS) is the more profitable company, earning 5.0% net margin versus -0.7% for Sonida Senior Living, Inc. — meaning it keeps 5.0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: FMS leads at 9.3% versus -4.9% for SNDA. At the gross margin level — before operating expenses — SNDA leads at 89.1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Is SNDA or FMS more undervalued right now?
Analyst consensus price targets imply the most upside for FMS: 19.4% to $28.00.
06Which pays a better dividend — SNDA or FMS?
In this comparison, SNDA (0.6% yield) pays a dividend. FMS does not pay a meaningful dividend and should not be held primarily for income.
07Is SNDA or FMS better for a retirement portfolio?
For long-horizon retirement investors, Fresenius Medical Care AG & Co. KGaA (FMS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.40)). Both have compounded well over 10 years (FMS: -28.5%, SNDA: -86.0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between SNDA and FMS?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. In terms of investment character: SNDA is a small-cap quality compounder stock; FMS is a mid-cap deep-value stock. SNDA pays a dividend while FMS does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.